An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.
Program will fund seven groups over five years in hope of Baby KJ-like successes
Jean-Christophe VERHAEGEN / AFP via Getty Images
By Jason MastJuly 9, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing Therapies
The Jackson Laboratory, with the Broad Institute and Partners, Selected for ARPA-H THRIVE Award to Advance Gene Editing Platform for Pediatric Epilepsies and Rare CNS Diseases
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
Why a gene-editing breakthrough has some experts worried | CNN
ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say…
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival…
Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing…
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
The Jackson Laboratory, with the Broad Institute and Partners, Selected for ARPA-H THRIVE Award to Advance Gene Editing Platform…
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The…
